← Back

Wire · regulatory

TOP-REAL's Digital Bet: Can eCOA Technology Solve the Toxicity Crisis Killing HER2+ ...

Published

22 November 2026

Topic

regulatory

◆ Sectors

Digital HealthMedtech

◆ Geography

United States

◆ Source

Read at clinicaltrialvanguard.com →

◆ Verified

Fusion42 · 22 November 2026 · Fusion42 review

The TOP-REAL study evaluates whether digital monitoring with electronic clinical outcome assessment (eCOA) technology can detect toxicities early enough in HER2-positive metastatic breast cancer patients to reduce treatment discontinuations, addressing a critical issue in real-world use of trastuzumab deruxtecan. The study also challenges current FDA guidance on remote safety monitoring and patient-reported outcomes by aiming to provide evidence for regulatory acceptance of eCOA data in cancer trial safety claims.

This Wire brief sits within Fusion42's coverage of Digital Health and Medtech.

◆ ◆ The Wire takeaway

You face a shift as regulators may soon accept digital symptom tracking to prove treatment safety in cancer trials. That opens a door to build eCOA tools that fill the critical timing gap in toxicity detection and keep patients on key therapies longer.

◆ Coverage

1 source · 22 Nov 2026

◆ Related on Wire

◆ Topics

Digital HealthMedtechecoa-technologybreast-canceroncology-trialsfda-guidancedigital-health